Business Context and Reporting Period
SciSparc Ltd. filed Form 6-K on January 13, 2026, reporting a material corporate development. The filing details a definitive asset purchase agreement entered into on January 8, 2026, with Xylo Technologies Ltd. ("Xylo").
Key Financial Metrics
The filing does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity for the reporting period. The document focuses exclusively on the terms of the pending acquisition.
Material Changes and Transaction Details
- Acquisition Target: SciSparc agreed to acquire Xylo's complete portfolio of patents, trademarks, know-how, brand names, and related intellectual property rights, including unregistered rights.
- Consideration: SciSparc will issue ordinary shares representing 19.99% of its issued and outstanding share capital at the closing date. Alternatively, the Company may elect to issue pre-funded warrants in lieu of shares.
- Closing Date: The transaction is expected to close on March 8, 2026, subject to customary conditions.
- Regulatory Obligations: SciSparc is obligated to file a registration statement with the SEC within 30 days of the closing date to register the resale of the issued shares.
Outlook, Risks, and Management Commentary
Management characterizes the acquisition as an entry into a "multi-billion dollar opportunity" in the endoscope market. The filing includes a cautionary note regarding forward-looking statements, noting that actual results may differ materially due to risks and uncertainties. Specific risks are referenced in the Company's Annual Report on Form 20-F filed on April 24, 2025. The Company disclaims any obligation to update forward-looking statements.
Investor Verification Checklist
- Verify the full text of the Asset Purchase Agreement (Exhibit 10.1) for specific closing conditions and representations.
- Confirm the exact number of shares or warrants to be issued once the closing share capital is finalized.
- Review the press release (Exhibit 99.1) for details on the specific patents and market opportunities.
- Monitor the filing of the required SEC registration statement for the resale of shares within 30 days of the March 8, 2026 closing.
- Assess the dilution impact of issuing 19.99% of the company's equity to Xylo.